These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8830231)

  • 1. [Monitoring of long QT interval during treatment of malaria with halofantrine].
    Nicolas X; Nicolas F
    Med Trop (Mars); 1995; 55(4):394-5. PubMed ID: 8830231
    [No Abstract]   [Full Text] [Related]  

  • 2. Sudden death in a traveller following halofantrine administration--Togo, 2000.
    Can Commun Dis Rep; 2001 Jul; 27(14):120-1, 124. PubMed ID: 11467177
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cardiac rhythm disturbances and prolonged QT interval with halofantrine].
    Lavallée I; Marc E; Moulin F; Treluyer JM; Imbert P; Gendrel D
    Arch Pediatr; 2001 Aug; 8(8):795-800. PubMed ID: 11524908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug alert: halofantrine.
    Wkly Epidemiol Rec; 1993 Sep; 68(37):269-70. PubMed ID: 8217579
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.
    McIntosh MP; Batey AJ; Coker SJ; Porter CJ; Charman WN
    J Pharm Pharmacol; 2004 Jan; 56(1):69-77. PubMed ID: 14980003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of halofantrine on QT interval in children.
    Siriez JY; Lupoglazoff JM; Bouchy-Bagros ML; Pull L; Denjoy I
    Pathog Glob Health; 2012 May; 106(2):124-5. PubMed ID: 22943550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of halofantrine in acute malaria.
    Bhattacharyya PC; Kakati S; Sarma PC; Saikia PK
    J Assoc Physicians India; 1993 Aug; 41(8):505-6. PubMed ID: 8294354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long QTc interval complicating halofantrine therapy in 2 children with Plasmodium falciparum malaria].
    Olivier C; Rizk C; Zhang D; Jacqz-Aigrain E
    Arch Pediatr; 1999 Sep; 6(9):966-70. PubMed ID: 10519031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prolonged QT interval and cardiac toxicity due to halofantrine].
    Fourcade L; Hovette P; De Pina JJ; Rault JP; Peyron F; Touze JE
    Med Trop (Mars); 1995; 55(2):182-3. PubMed ID: 7565005
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravascular haemolysis following treatment of malaria with halofantrine: case report.
    Fehintola FA; Falade CO; Sowunmi A
    Niger J Clin Pract; 2006 Dec; 9(2):174-5. PubMed ID: 17319353
    [No Abstract]   [Full Text] [Related]  

  • 11. Halofantrine-induced pruritus amongst subjects who itch to chloroquine.
    Ezeamuzie IC; Igbigbi PS; Ambakederemo AW; Abila B; Nwaejike IN
    J Trop Med Hyg; 1991 Jun; 94(3):184-8. PubMed ID: 1828840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation.
    Gundersen SG; Rostrup M; von der Lippe E; Platou ES; Myrvang B; Edwards G
    Scand J Infect Dis; 1997; 29(2):207-8. PubMed ID: 9181664
    [No Abstract]   [Full Text] [Related]  

  • 13. Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine.
    Lightbown ID; Lambert JP; Edwards G; Coker SJ
    Br J Pharmacol; 2001 Jan; 132(1):197-204. PubMed ID: 11156578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices.
    Leite EA; Grabe-Guimarães A; Guimarães HN; Machado-Coelho GL; Barratt G; Mosqueira VC
    Life Sci; 2007 Mar; 80(14):1327-34. PubMed ID: 17303179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Halofantrine in the treatment of uncomplicated falciparum malaria with a three-dose regimen in Papua New Guinea: a preliminary report.
    Hombhanje FW; Kereu RK; Bulungol P; Paika R
    P N G Med J; 1998 Mar; 41(1):23-9. PubMed ID: 10741174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome.
    Toivonen L; Viitasalo M; Siikamäki H; Raatikka M; Pohjola-Sintonen S
    Clin Cardiol; 1994 Jul; 17(7):403-4. PubMed ID: 8088027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac complications of halofantrine: continuous electrocardiographic study (holter) in 20 patients].
    Monlun E; Le Metayer P; Receveur MC; Bouabdallah K; Neau D; Longy-Boursier M; Le Bras M
    Rev Med Interne; 1993; 14(10):954. PubMed ID: 8009050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac complications of halofantrine: a prospective study of 20 patients.
    Monlun E; Le Metayer P; Szwandt S; Neau D; Longy-Boursier M; Horton J; Le Bras M
    Trans R Soc Trop Med Hyg; 1995; 89(4):430-3. PubMed ID: 7570888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged QT interval with halofantrine.
    Monlun E; Pillet O; Cochard JF; Favarel Garrigues JC; le Bras M
    Lancet; 1993 Jun; 341(8859):1541-2. PubMed ID: 8099420
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A.
    Piippo K; Holmström S; Swan H; Viitasalo M; Raatikka M; Toivonen L; Kontula K
    Am J Cardiol; 2001 Apr; 87(7):909-11. PubMed ID: 11274952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.